Physician profile
Emery I Salom
NPI 1952396459
$29,993.76
in general payments reported to CMS, 2019-2025
42 companies · $1,554 in 2025
The $1,554 reported for 2025 was more than what 75% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,319 · 2021: $11K · 2022: $1,472 · 2023: $1,274 · 2024: $2,652 · 2025: $1,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,762 · Consulting Fee: $1,610 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,762.40 |
| Consulting Fee | $1,610.00 |
| Education | $107.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20,828.65 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $1,672.00 | 2024 | Xpovio |
| Gynesonics, INC. | $1,414.67 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $659.25 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals Lp | $641.64 | 2019-2025 | Lynparza |
| Myriad Genetic Laboratories, INC. | $581.42 | 2021-2025 | Myrisk, Precisetumor |
| Hologic Sales and Service, LLC | $407.59 | 2019-2024 | Acessa Provu System |
| Glaxosmithkline, LLC. | $398.95 | 2020-2025 | Jemperli, Zejula |
| Intuitive Surgical, INC. | $360.92 | 2022-2025 | Da Vinci Surgical System |
| Eisai INC. | $324.62 | 2019-2025 | |
| Clovis Oncology, INC. | $293.01 | 2019-2022 | |
| Astellas Pharma US INC | $235.50 | 2023-2025 | Veozah |
| Seagen INC. | $228.87 | 2021-2023 | Tivdak |
| Pfizer INC. | $198.67 | 2022-2025 | |
| Medtronic, INC. | $168.04 | 2021-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $138.75 | 2019-2023 | Olympus |
| Sumitomo Pharma America, INC. | $131.75 | 2023 | Myfembree |
| Meditrina | $127.68 | 2024 | |
| Minerva Surgical, INC | $125.02 | 2022-2023 | |
| Heron Therapeutics, INC. | $121.84 | 2025 | Aponvie, Zynrelef |
| Covidien Lp | $121.19 | 2019 | |
| Ethicon US, LLC | $94.60 | 2019-2023 | Stratafix |
| Caris Mpi, INC. | $93.80 | 2025 | Mi Cancer Seek |
| Olympus Corporation of The Americas | $84.87 | 2019 | |
| Fennec Pharmaceuticals, INC. | $65.11 | 2024-2025 | Pedmark, Fyarro |
| Coopersurgical, INC. | $53.40 | 2023-2025 | Paragard T 380a, Ally II Ups, Paragard T 380a |
| Tesaro, INC. | $53.30 | 2019 | |
| Axogen | $47.07 | 2019 | |
| Foundation Medicine, INC. | $42.23 | 2019-2020 | |
| Allergan, INC. | $39.33 | 2019 | |
| Biom'Up France Sas | $33.07 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.87 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $27.79 | 2019 | |
| Daiichi Sankyo INC. | $27.77 | 2025 | Enhertu |
| Verastem, INC. | $22.90 | 2025 | Avmapki Fakzynja Co-Pack |
| Amgen INC. | $18.19 | 2020 | |
| Innovation Technologies INC | $17.96 | 2025 | Irrisept |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Genentech USA, INC. | $15.03 | 2019 | |
| Axonics, INC. | $14.39 | 2023 | Axonics |
| Immunogen, INC. | $13.70 | 2023 | Elahere |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emery Salom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.